Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy

Plain-language summary

This study aims to identify genes that could predict cancer recurrence in women with breast cancer treated with chemotherapy. It included patients with node-positive or high-risk node-negative disease who had received anthracycline-containing chemotherapy (enrolled on ECOG-E2197). It is an observational (non-phase) study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Eastern Cooperative Oncology Group

Intervention

microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis

Start date

10/7/2005

Estimated completion

10/8/2005

Related genes

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

DISEASE CHARACTERISTICS:

* Diagnosis of breast cancer

  * Node positive OR high-risk node negative disease
  * Tumor \> 1.0 cm in diameter
* No locally advanced, inflammatory, or metastatic breast cancer
* Previously treated with 4 courses of anthracycline-containing chemotherapy (i.e., doxorubicin and docetaxel OR doxorubicin and cyclophosphamide)
* Enrolled on clinical trial ECOG-E2197
* Adequate tumor material available in ECOG Pathology Coordination Center
* Previously consented to future cancer-related research
* Hormone receptor status known

PATIENT CHARACTERISTICS:

* Female
* Menopausal status not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics